CTRI/2010/091/000679已完成3 期
A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion
ovartis Healthcare Pvt Ltd0 个研究点目标入组 676 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 676
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria at Baseline:
- •Male or female renal allograft recipients at least 18 years old.
- •Written informed consent.
- •Patient receiving a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor.
- •Cold ischemia time (CIT) less than 24 hours.
- •Negative pregnancy test for female patients.
- •Inclusion Criteria at Randomization:
- •Patients on CNI (TAC or CsA) + Myfortic + steroids.
- •Serum creatinine less than 2.8 mg/dL (250 mol/L) and an actual eGFR (MDRD4)greater than or equal to 25 mL/min/1.73m exp2 (without renal replacement therapy).
排除标准
- •Exclusion Criteria at Baseline:
- •1)Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
- •2)Recipient of multiple organ transplants.
- •3)Recipient of ABO incompatible allograft or a positive cross-match.
- •4)Panel Reactive Antibodies (PRA) level greater than equal to 30 %.
- •5)Positive test for human immunodeficiency virus (HIV).
- •6)Patient receiving an allograft from a Hepatitis B surface Antigen (HBsAg) or a Hepatitis C Virus (HCV) positive donor.
- •7)HBsAg and/or a HCV positive patient with evidence of elevated LFTs (ALT/AST levels greater than equal to 2.5 times ULN).
- •8)Severe restrictive or obstructive pulmonary disorders.
- •9)Patient with severe allergy requiring acute or chronic treatment or hypersensitivity to any of the study drugs or similar drugs.
- •10)Severe hypercholesterolemia or hypertriglyceridemia.
- •11)Low platelet count.
- •12)Low white blood cell count.
- •13)History of malignancy of any organ system
- •Exclusion Criteria at Randomization:
- •14)Graft loss.
- •15)Patient on renal replacement therapy.
- •16)Patient who experienced severe humoral and/or cellular rejection (BANFF greater than equal to IIb).
- •17)Patient with greater than equal to 2 episodes of AR or an AR episode that needed antibody treatment.
- •18)Patient with ongoing or currently treated AR (2 weeks prior to randomization).
- •19)Proteinuria greater 1 g/day.
- •20)Patients with recurrence of Focal Segmental Glomerulosclerosis (FSGS).
- •21)Low platelet count; Low white blood cell count; Low absolute neutrophil count; Low hemoglobin.
- •22)Severe liver disease.
- •23)Systemic infection requiring continued therapy that would interfere with the objectives of the study.
- •24)Severe hypercholesterolemia or hypertriglyceridemia.
- •25)Patients with ongoing wound healing problems, clinically significant infection requiring continued therapy.
- •26)Presence of intractable immunosuppressant complications or side effects.
- •27)Patients on anticoagulants that prevents renal allograft biopsy.
- •28)Use of prohibited medication.
- •29)Use of immunosuppressive agents not utilized in the protocol.
- •30)Pregnant or nursing (lactating) women.
- •31)Women of child-bearing potential not using a highly effective method of birth control.
研究者
相似试验
已完成
3 期
A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion (CRAD001A2429, ELEVATE study)niertransplantatierenal transplantation10038430NL-OMON34407ovartis90
进行中（未招募）
不适用
A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients. - NDEUCTR2007-001821-85-ITOVARTIS FARMA690
进行中（未招募）
不适用
A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients.EUCTR2007-001821-85-NLovartis Pharma Services AG690
进行中（未招募）
不适用
A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration controlled everolimus to eliminate or to reduce tacrolimus compared to tacrolimus in de novo liver transplant recipients.liver transplantationEUCTR2007-001821-85-FRovartis Pharma Services AG690
进行中（未招募）
不适用
A 24 month study to test everolimus in patients who have had a liver transplantImmunosuppression in liver transplantationMedDRA version: 13.1Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 13.1Level: LLTClassification code 10021510Term: Immunosuppression NOSSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 13.1Level: PTClassification code 10062016Term: ImmunosuppressionSystem Organ Class: 10021428 - Immune system disordersEUCTR2007-001821-85-SEovartis Pharma Services AG690